content: SECURITIES AND EXCHANGE COMMISSION
  
                               WASHINGTON, D.C. 20549
  
                      ---------------------------------------
  
  
                                      FORM 8-K
  
                                   CURRENT REPORT
  
                       PURSUANT TO SECTION 13 OR 15(d) OF THE
                           SECURITIES EXCHANGE ACT OF 1934
  
           Date of report (Date of earliest event reported): July 14, 2003
                                                             -------------
  
                                 CYTOGEN CORPORATION
               ------------------------------------------------------
                 (Exact Name of Registrant as Specified in Charter)
  
             Delaware                     000-14879                 222322400
  ----------------------------    ------------------------    --------------------
  (State or Other Jurisdiction    (Commission File Number)     (I.R.S. Employer
        of Incorporation)                                      Identification No.)
  
   650 College Road East, CN 5308, Suite 3100, Princeton, NJ            08540
  ----------------------------------------------------------       ---------------
          (Address of Principal Executive Offices)                    (Zip Code)
  
         Registrant's telephone number, including area code: (609) 750-8200
                                                             --------------
  
  
  <PAGE>
  ITEM 5.     OTHER EVENTS AND REQUIRED FD DISCLOSURE.
  
           In June 1999, Progenics Pharmaceuticals, Inc. and Cytogen Corporation
  (collectively, the "Members") formed a joint venture in the form of a mutually
  owned limited liability company (the "JV") for the purpose of conducting
  research, development, manufacturing and marketing for products relating to
  prostate-specific membrane antigen.
  
           As previously disclosed, the Members had been negotiating the 2003
  annual budget for the joint venture and the terms of a new services agreement
  pursuant to which the Members would provide research, development and related
  services to the JV.
  
           In July 2003, the Members: (i) agreed to an updated work plan governing
  the activities of the JV for the remainder of 2003, including the execution of
  various third-party contracts; (ii) agreed to a budget for the JV's operations
  for 2003 and related capital contributions of the parties; and (iii) agreed to
  an amended services agreement pursuant to which the Members will provide
  research, development and related services for the remainder of 2003. The JV
  work plan, budget, and other operational and financial matters relating to
  periods after 2003 will require the further agreement of the Members.
  
           On July 14, 2003, the Members issued a joint press release announcing
  the above referenced agreements. Such press release is attached hereto as
  Exhibit 99.1, and is incorporated herein by reference. The foregoing description
  of such press release is qualified in its entirety by reference to such
  document.
  
  ITEM 7.     FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.
  
         (c)     Exhibits.
  
                   Exhibit No.      Description
                   -----------      -----------
                      99.1          Press release dated July 14, 2003.
  
  
  
  <PAGE>
  
  
                                     SIGNATURES
  
  
  
           Pursuant to the requirements of the Securities Exchange Act of 1934,
  the Registrant has duly caused this current report on Form 8-K to be signed on
  its behalf by the undersigned hereunto duly authorized.
  
                                     CYTOGEN CORPORATION
  
  
                                     By:   /s/ Michael D. Becker
                                          ----------------------------------------
                                          Michael D. Becker
                                          President and Chief Executive Officer
  
  Dated:   July 14, 2003
  
  
  
  <PAGE>
  
  
                                    EXHIBIT INDEX
  
  
                        Exhibit No.       Description
                        -----------       -----------
                            99.1          Press release dated July 14, 2003.
metadata_documents: [{"type": "8-K", "sequence": "1", "filename": "form8k071403.txt", "description": "FORM 8-K DATED JULY 14, 2003", "secsgml_size_bytes": 4134}]
metadata_filer: {"company-data": {"conformed-name": "CYTOGEN CORP", "cik": "0000725058", "assigned-sic": "2835", "irs-number": "222322400", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-14879", "film-number": "03785236"}, "business-address": {"street1": "600 COLLEGE RD EAST CN 5308", "city": "PRINCETON", "state": "NJ", "zip": "08540", "phone": "6099878200"}, "mail-address": {"street1": "600 COLLEGE RD EAST CN 5308", "street2": "600 COLLEGE RD EAST CN 5308", "city": "PRINCETON", "state": "NJ", "zip": "08540"}}
text: SECURITIES AND EXCHANGE COMMISSION
  
                               WASHINGTON, D.C. 20549
  
                      ---------------------------------------
  
                                      FORM 8-K
  
                                   CURRENT REPORT
  
                       PURSUANT TO SECTION 13 OR 15(d) OF THE
                           SECURITIES EXCHANGE ACT OF 1934
  
           Date of report (Date of earliest event reported): July 14, 2003
                                                             -------------
  
                                 CYTOGEN CORPORATION
               ------------------------------------------------------
                 (Exact Name of Registrant as Specified in Charter)
  
             Delaware                     000-14879                 222322400
  ----------------------------    ------------------------    --------------------
  (State or Other Jurisdiction    (Commission File Number)     (I.R.S. Employer
        of Incorporation)                                      Identification No.)
  
   650 College Road East, CN 5308, Suite 3100, Princeton, NJ            08540
  ----------------------------------------------------------       ---------------
          (Address of Principal Executive Offices)                    (Zip Code)
  
         Registrant's telephone number, including area code: (609) 750-8200
                                                             --------------
  ITEM 5.     OTHER EVENTS AND REQUIRED FD DISCLOSURE.
  
           In June 1999, Progenics Pharmaceuticals, Inc. and Cytogen Corporation
  (collectively, the "Members") formed a joint venture in the form of a mutually
  owned limited liability company (the "JV") for the purpose of conducting
  research, development, manufacturing and marketing for products relating to
  prostate-specific membrane antigen.
  
           As previously disclosed, the Members had been negotiating the 2003
  annual budget for the joint venture and the terms of a new services agreement
  pursuant to which the Members would provide research, development and related
  services to the JV.
  
           In July 2003, the Members: (i) agreed to an updated work plan governing
  the activities of the JV for the remainder of 2003, including the execution of
  various third-party contracts; (ii) agreed to a budget for the JV's operations
  for 2003 and related capital contributions of the parties; and (iii) agreed to
  an amended services agreement pursuant to which the Members will provide
  research, development and related services for the remainder of 2003. The JV
  work plan, budget, and other operational and financial matters relating to
  periods after 2003 will require the further agreement of the Members.
  
           On July 14, 2003, the Members issued a joint press release announcing
  the above referenced agreements. Such press release is attached hereto as
  Exhibit 99.1, and is incorporated herein by reference. The foregoing description
  of such press release is qualified in its entirety by reference to such
  document.
  
  ITEM 7.     FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.
  
         (c)     Exhibits.
  
                   Exhibit No.      Description
                   -----------      -----------
                      99.1          Press release dated July 14, 2003.
  SIGNATURES
  
           Pursuant to the requirements of the Securities Exchange Act of 1934,
  the Registrant has duly caused this current report on Form 8-K to be signed on
  its behalf by the undersigned hereunto duly authorized.
  
                                     CYTOGEN CORPORATION
  
                                     By:   /s/ Michael D. Becker
                                          ----------------------------------------
                                          Michael D. Becker
                                          President and Chief Executive Officer
  
  Dated:   July 14, 2003
  EXHIBIT INDEX
  
                        Exhibit No.       Description
                        -----------       -----------
                            99.1          Press release dated July 14, 2003.